Related Experiment Video

Updated: May 1, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K

A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors

Serkan Akin1, Taner Babacan, Furkan Sarici

  • 1Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.

Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|March 25, 2014
PubMed

Insights

Cyclin dependent kinase inhibitors (CDKIs) are emerging targeted therapies for breast cancer. Palbocyclib, a promising CDKI, shows favorable progression-free survival in estrogen receptor-positive breast cancer, advancing to phase III trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Breast cancer is a leading global cancer in women.
  • Understanding tumor biology is crucial for effective treatment selection.
  • Cell cycle alterations are common in breast cancer development.

Purpose of the Study:

  • To highlight the role of cyclin dependent kinase inhibitors (CDKIs) as targeted therapies in breast cancer.
  • To discuss the potential of Palbocyclib as a CDKI for breast cancer treatment.

Main Methods:

  • Review of current research on CDKIs in breast cancer.
  • Analysis of Palbocyclib's efficacy based on phase II trial data.

Main Results:

  • CDKIs, including selective and non-selective inhibitors, are investigated for breast cancer.
  • Palbocyclib demonstrated favorable progression-free survival in phase II trials.
  • Palbocyclib is progressing to phase III trials for estrogen receptor-positive breast cancer.

Conclusions:

  • Palbocyclib represents a promising targeted therapy for breast cancer.
  • Further clinical trials are warranted to confirm Palbocyclib's efficacy and safety.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.3K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

6.8K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.3K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K